Loading…
← CockpitCompetitor Analysis › IPCALAB.NS IPCA LaboratoriesOpen in the cockpit ↗

IPCA LaboratoriesIPCALAB.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Indian pharma maker of branded generics for India plus a large export API business, strong in anti-malarials and pain drugs.

≈ India's API-heavy generics makerMomentum strong 64
Mkt cap
$5.03B
US dollars, full cap
Free float
54%
of shares outstanding
$/day
$5.55M
20-day average traded
Fwd P/E
31.1×
forward earnings
ROIC−WACC
+3.8 pp
WACC 9.4%
Hurdle
+4 pp
Req g minus delivered
Next earnings
91 days
17 Feb 2027
Close · INR₹1,854
1D+1.1%
1W-4.3%
1M+2.2%
3M-1.5%
6M+11.9%
YTD+30.7%
1Y+38.3%
ATR %3.4%
Beta0.01
52w lowhigh9.0% off high

What IPCA Laboratories does

Indian pharma maker of branded generics for India plus a large export API business, strong in anti-malarials and pain drugs.

Earns from two engines: branded medicines prescribed by Indian doctors and sold through pharmacies, and active ingredients sold in bulk to other drugmakers abroad, which it makes itself rather than buying in. Anti-malarial drugs sold into WHO-backed tenders are a niche line. It took control of Unichem Laboratories, another Indian drugmaker, in 2023.

In one line: India's API-heavy generics maker.

Products and services

  • APIs (export)
  • India branded formulations (pain, cardiac)
  • Anti-malarials
  • Institutional/tender business (WHO)

Customers

  • Global API buyers/generic makers
  • Indian retail pharmacies
  • WHO/government tenders (anti-malarials)

Where it sits in the supply chain

  • Pharmaceuticals
  • API manufacturing (exports)
  • India branded formulations

What could go right

  • Export API demand growth
  • Domestic chronic therapy expansion

What could go wrong

  • FDA/regulatory plant inspection risk
  • API price competition from China

Moat: narrow (scale, process know-how). Large backward-integrated API capacity gives cost and supply advantages over pure formulators.

Headquarters: Mumbai, India · Founded: 1949 · Employees: 23,467

Named competitors

IPCA Laboratories at a glance

Size IPCA Laboratories (IPCALAB.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $5.03B, the 213th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,854 on 18 Nov 2026.

Performance Over six months the shares gained 11.9%, against +10.5% for the median peer and +3.8% for the India market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 12.0% over the last twelve months (peer median +11.4%); the operating margin is 18.4% (peer median 21.2%).

Valuation It trades at 31.1× forward earnings against a peer median of 25.8× (8th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.8 points above its cost of capital (9.4% WACC).

Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011012021 May 202621 Aug 202618 Nov 2026IPCALAB.NS 113Peer median 112
Six months, rebased to 100: IPCA Laboratories against the median of its 20 peers (local-currency closes).

IPCA Laboratories financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹105B₹95.6B₹88.5B₹76.1B₹62.0B
Revenue growth—+8%+16%+23%—
Gross profit₹47.9B₹35.0B₹28.5B₹21.9B₹16.9B
EBITDA₹23.7B₹20.3B₹17.2B₹11.6B₹9.93B
Net income₹14.0B₹11.4B₹7.38B₹5.47B₹4.71B
Free cash flown/a₹4.42B₹5.00B₹4.83B₹3.26B
Capital expendituren/a₹6.56B₹7.76B₹4.11B₹4.94B
Total debt₹7.53B₹8.09B₹13.6B₹14.4B₹14.8B

Quarterly statements and history in the cockpit →

IPCA Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+20%PTCT326030LQDA600085600079ERASTVTXMANEGLAXO6885784506EMCUREIONS6030870874GLANDAJANTPHARM600566CAMXABBOTINDIAIPCALAB.NS6-month return →1-month return →
Up and to the right = strong over both horizons. IPCA Laboratories is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%+800%20×40×PTCT326030LQDA600085600079TVTXGLAXO6885784506EMCURE6030870874GLANDCAMXIPCALAB.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. IPCA Laboratories is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%0%200%400%PTCT326030LQDA600085GLAXO688578IPCALAB.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. IPCA Laboratories is the large dot.

IPCA Laboratories competitors and peer comparison

Head to head with its named competitors (IPCALAB.NS vs DIVISLAB.NS vs AUROPHARMA.NS vs CIPLA.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
IPCA Laboratories IPCALAB.NS$5.03B+12%+12%18%31.1×16.5%
Divi's Laboratories DIVISLAB.NS$31.3B+60%+22%34%73.5×47.1%
Aurobindo Pharma AUROPHARMA.NS$11.0B+19%+14%15%22.3×21.1%
Cipla CIPLA.NS$12.2B+1%-1%13%29.1×28.4%
Torrent Pharmaceuticals TORNTPHARM.NS$18.8B+3%+42%22%70.2×37.6%

How IPCA Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

IPCA Laboratories against its 20 peers (data as of 18 Nov 2026)
MeasureIPCALAB.NSPeer medianRank in peer set
1-month return+2.2%-1.2%9th highest of 21
6-month return+11.9%+10.5%7th highest of 21
Distance from 52-week high-9.0%-24.4%6th highest of 21
Revenue growth (TTM)+12.0%+11.4%10th highest of 19
Operating margin18.4%21.2%8th lowest of 19
Forward P/E31.1×25.8×8th most expensive of 18
Growth the price implies (Req g, 7 yrs)16.5%5.8%5th most demanding of 17
Growth delivered (Del g)+12.2%+13.0%8th lowest of 17
Hurdle (Req g minus delivered)+4.3 pp-3.6 pp4th most demanding of 17
ROIC minus cost of capital+3.8 pp+5.8 pp8th lowest of 17
EV / EBITDA20.3×22.8×5th cheapest of 11
Net debt / EBITDA-0.1×-0.8×4th most indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
IPCA Laboratories IPCALAB.NSIndia$5.03B+12%+12%18%31.1×16.5%+12.2%
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%31.2×6.6%+35.4%
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%21.5×-4.4%+93.6%
Liquidia LQDAUnited States$5.08B-9%+798%47%13.8×5.0%+192.5%
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%28.7×1.7%+6.2%
Humanwell Healthcare (Group) 600079.SSChina$4.87B+11%+2%15%13.8×-8.8%+3.0%
Erasca ERASUnited States$4.83B+24%n/an/an/an/an/a
Travere Therapeutics TVTXUnited States$4.82B+16%+49%-3%17.1×17.3%+19.9%
Veradermics MANEUnited States$5.27B+19%n/an/an/an/an/a
GlaxoSmithKline Pharmaceuticals GLAXO.NSIndia$4.79B+10%+12%33%37.3×26.4%+5.5%
Shanghai Allist Pharmaceuticals 688578.SSChina$5.32B-14%+39%47%12.4×0.1%+519.6%
Sumitomo Pharma 4506.TJapan$5.33B+11%+11%10%8.6×1.7%-2.6%
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%33.6×15.9%+12.7%
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%n/an/an/a
Gan & Lee Pharmaceuticals 603087.SSChina$5.59B+11%+14%20%25.8×n/an/a
Guangzhou Baiyunshan Pharmaceutical 0874.HKHong Kong$4.48B-23%+6%3%7.0×1.3%+4.0%
Gland Pharma GLAND.NSIndia$5.71B+44%+22%21%39.3×20.2%+13.3%
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%31.7×23.8%+13.8%
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%16.2×-9.9%+0.3%
Camurus CAMX.STSweden$4.36B+36%+3%38%45.1×7.9%+46.5%
Abbott India ABBOTINDIA.NSIndia$5.80B-8%+7%28%31.1×8.0%+10.0%

Questions

Who are IPCA Laboratories's main competitors?
Named competitors: Divi's Laboratories (DIVISLAB.NS), Aurobindo Pharma (AUROPHARMA.NS), Cipla (CIPLA.NS), Torrent Pharmaceuticals (TORNTPHARM.NS). The cockpit's measured peer set (industry) also includes PTC Therapeutics (PTCT), SKBP (326030.KS), Liquidia (LQDA), Beijing TongRenTang (600085.SS), Humanwell Healthcare (Group) (600079.SS), Erasca (ERAS).
Is IPCA Laboratories expensive compared with its peers?
On forward p/e it trades at 31.1× against a peer median of 25.8×, 8th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has IPCA Laboratories stock performed?
Over six months to 18 Nov 2026 the shares returned +11.9% against +10.5% for the median peer; over one year +38.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.